Drug Channel Updates
Timely updates on drug shortages, launches, recalls, and more.
Top shortages
Albut/Iprat Ah 2.5-0.5mg/3ml 6×5 UD Increased demand.
Budesonide Ah 0.5mg/2ml 30x3UD Manufacturing delays.
Dorzolamide Hcl Dr 2% Capacity restraint.
Lidocaine Ap 5% 30s Ongoing issues.
Naltrexone Hcl Tb 50mg 30s Increased demand.
Naltrexone Hcl Tb 50mg 100s Increased demand.
Drug Launches
The latest insights on the drug market.
Recent Launches
Sandostatin LAR (octreotide acetate)launched March 19 and is a $76 million name-brand market. Only the 10mg launched. The 20mg is expected to launch in the next 60 days. Teva is the source vendor.
Auryxia (ferric citrate) launched arch 20th and is a $249 million market. Viatris is our source vendor.
Upcoming Launches
Osymia (phetermine hydrochloride topiramate) is a $51 million market. Launch seems to be imminent. Teva will be our source vendor. No other entrants are expected at this time.
Anora Ellipta (umeclidinium bromide: vilanterol trifenate) is a $1.1 billion market. Expected launch around mid-April Prasco will be our source vendor and no other.
Complera (tolvaptan) is a $1.1 billion market. Expected to launch late April or May.
Jynarque (tolvaptan) is a $1.3 billion market. Expected to launch late April or May. (Note: This is a specialty item with limited retail sales.)
Brilinta (tolvaptan) is a $1.3 billion market. Expected to launch (60mg strength) mid-summer with only one supplier. However, the 90mg is anticipated to have multiple suppliers.
Aptiom (eslicarbazepine) is a $376 million market. Expected during May. Pediatric exclusivity shared with several players.
Promacta (eltrombopag) is a $2 billion market. Expected sometime this summer.
Day 181
Betimol (timolol) is a $<10 million. It will be available to others in June.
Lucemyra (lofexidine) is a $16 million market. It’s available now.
Mesnex (mesna) is a $6 million market. Available in July.
Motegrity (prucalopride succinate) is a $161 million market. It will be available in June.
Namzaric 14mg-10mg & 28mg-10mg (mesna) is a $70 million market. Available in July.
Stendra (avanafil) is less than a $<10 million market, and will be available to others in May.
Recalls
The most recent recall information with return forms.
Dr. Reddy’s
Company Name: Dr. Reddy’s Laboratories Ltd.
Product Description: Levetiracetam in Sodium Chloride Injection
Recall Reason: Mislabeling of infusion bag
Vitality
Company Name: One Source Nutrition
Product Description: Vitality male enhancement dietary supplement capsules
Recall Reason: Undeclared Sildenafil and Tadalafil